Gain Therapeutics CFO to resign, CEO to serve as interim finance chief

Gain Therapeutics, Inc. disclosed in a Form 8-K dated September 22, 2026 that Gianluca Fuggetta, Senior Vice President of Finance, principal financial officer, and principal accounting officer of the company, told the company he plans to step down from his positions, with his departure taking effect on September 30, 2026, so he can pursue other opportunities.¹

Two days later, the company's board of directors named Gene Mack, who currently serves as President and Chief Executive Officer, to also take on the role of interim Chief Financial Officer, starting October 1, 2026.¹ Under the arrangement, Mack will keep his President and CEO titles while additionally handling the principal financial officer and principal accounting officer functions until a successor is named or until he leaves or is removed from the interim post, and until a permanent replacement is found.¹

The company said it is actively searching for a permanent principal financial officer and principal accounting officer.¹

The filing notes that Mack's biographical details were previously included in the company's Annual Report on Form 10-K filed on March 26, 2026, and are incorporated into this filing by reference.¹ It also states that the compensation and other material terms of Mack's employment will not change as a result of this appointment.¹

The company further disclosed that there are no arrangements between Mack and any other party related to his selection as interim CFO, no family relationship between Mack and other company directors or executive officers, and no direct or indirect interest by Mack in any transaction requiring disclosure under Item 404(a) of Regulation S-K.¹

The 8-K was signed by Mack in his capacity as Chief Executive Officer on September 28, 2026.